The use of drugs like Ozempic, Wegovy and Zepbound in people with type 1 diabetes has risen sharply over the past decade, a ...

THE ‘King Kong’ of fat jabs could help dieters keep weight off for three years, a study has revealed. Italian scientists ...

Eli Lilly's foray into telehealth shows the emerging importance virtual care platforms are playing in the rising popularity ...

The recent uptick and rise in popularity of GLP-1 drugs for addressing weight loss and obesity has led to an increase in U.S. litigation ...

Mounjaro, a new treatment for Type 2 diabetes and obesity, has been launched in India after CDSCO approval. The drug, ...

As obesity rates rise among individuals with T1D, GLP-1 agonist medications, indicated for T2D and weight loss, are ...

A study from the Arkansas Agricultural Experiment Station finds that GLP-1 medications, such as Ozempic and Wegovy, are ...

The market for anti-obesity drugs has been growing for a while, but is finally about to take off with the entry of two global ...

The prevalence of U.S. adults without diabetes who filled a GLP-1 receptor agonist prescription rose from 0.1% in 2018 to 0.4 ...

Lately, however, Eli Lilly's stock has cooled. Shares have been essentially flat since July 2024. The market for GLP-1 ...

The family of medications called GLP-1 receptor agonists includes drugs like Wegovy, Zepbound, Ozempic, Mounjaro and Victoza. They were originally developed to treat type 2 diabetes, which happens ...

As new weight-loss drugs like Ozempic reshape cultural norms around weight, some in recovery are finding that their trust in ...